Adrenomed develops a first-in-class monoclonal antibody (Adrecizumab) that targets the vasoactive Adrenomedullin system as a new strategy for causative and safe treatment of acute circulatory failure, e.g. septic shock.
EndoStim is marketing a device for the treatment of Gastro-esophageal Reflux Disease (GERD), commonly known as acid reflux, via electrical stimulation of the lower esophageal sphincter.
Genkyotex (EPA: GKTX) is developing first-in-class selective inhibitors of NOX enzymes for an orphan fibrotic disease as well as for angiogenesis, pain and inflammation.
ImevaX develops a novel therapeutic vaccine for treatment of Helicobacter pylori, the cause of gastric cancer, by targeting essential bacterial immune evasion factors.
Immatics is developing Adoptive Cell Therapy (ACT) and soluble T cell receptor (sTCR) approaches based on the company's unrivalled XPRESIDENT cancer target discovery platform.
Middle Peak Medical is developing new minimally invasive, catheter-based treatment options for mitral valve disease. It was acquired by Symetis in 2017.
NEUWAY Pharma is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.
Oxford Immunotec (NASDAQ: OXFD) focuses on developing and commercializing proprietary tests for latent tuberculosis and management of immune-regulated conditions.
Sensimed has developed a digital contact lens with telemetry features - the Triggerfish® - that provides automated 24h recording of continuous ocular dimensional / intraocular pressure changes for Glaucoma management.
SuperSonic Imagine (EPA:SSI) markets a unique imaging system combining shear wave elastography with conventional ultrasound, a new method to visualize soft tissues and diffentiate malignant from normal tissues at early tumor stages.
Themis is developing vaccines to prevent infectious diseases based on its Themaxyn™ platform with an emphasis on emerging tropical diseases and large unmet need indications.
